Research Funding
The ECD Global Alliance is dedicated to enhancing all research and knowledge of Erdheim-Chester disease through supporting leading medical research. The ECD Global Alliance funds research dedicated to exploring the diagnosis, cause, treatments, and cure of Erdheim-Chester Disease.
In addition, the organization works with research teams and patients around the world to facilitate communication between the two groups.
Overview
The ECD Global Alliance is dedicated to enhancing all research and knowledge of Erdheim-Chester disease through supporting leading medical research. The ECD Global Alliance funds research dedicated to exploring the diagnosis, cause, treatments, and cure of Erdheim-Chester Disease.
In addition, the organization works with research teams and patients around the world to facilitate communication between the two groups.
Grant Applications and Review Process
A call for Letters of Intent (LOI) is sent out to all known avenues for dissemination and is posted on the ECD Global Alliance website. Submitted LOIs (Letters of Intent) are reviewed by a committee of qualified researchers and clinicians. The investigators submitting projects that hold the most promise for making a significant and lasting advance in the knowledge and treatment of ECD are then invited to submit a complete proposal.
A Grant Application Review (GAR) Committee made up of qualified researchers is assembled to review submitted application proposals. Individuals on the committee first review each application independently. The GAR Committee then comes together as a group to share comments and discuss each application submitted. This committee provides the ECD Global Alliance Board of Directors with a ranking order of the applications. The Board of Directors then makes the final funding decision and notifies the applicants. Letters of Intent are submitted via an LOI submission form and are reviewed per an LOI Review Process and criteria. Invited proposals are then submitted and reviewed according to the ECDGA Grant Application Process.
Current Grant Opportunities: Early Career Investigator Grant
The ECDGA announces new funding cycles every year. If you are interested in receiving information about funding cycles, please register with the organization here.
The Erdheim-Chester Disease Global Alliance is pleased to announce a funding opportunity for Erdheim-Chester Disease and adult histiocytic disorders. Up to $60,000 USD will be awarded.
Letters of Intent are due November 28, 2026. This is a significant opportunity for all Early Career Investigators, defined as an individual who has not received previous funding for the study of ECD and is within ten (10) years of receiving their terminal degree or equivalent training. All Early Career Investigators are urged to apply.
Grant Funding
Guidelines
Submission Form
Announcement
Template
Template
Previous Grants Awarded
In April 2010, only one month after receiving a 501(c)(3) designation, the ECD Global Alliance (ECDGA) announced it would be awarding a $50,000 ECD research grant and requested proposals to the international medical research community. In November 2010, the first grant recipient was chosen. Since then, the organization has awarded an annual $50,000 research grant to study Erdheim-Chester Disease and a $316,000 grant to establish an ECD Patient Registry. Additionally, grant collaborations with partners have been made to expand the research investments for ECD.

Advanced Proteomic Profiling of Histiocytic Neoplasms: Uncovering Biomarkers and Mechanistic Insights for Enhanced Diagnosis and Therapeutic Strategies
Oshrat Hershkovitz-Rokah
Assuta Medical Center
$60,000
2026

Geographic and Resource-Based Variation in Diagnosis and Treatment Patterns in ECD and Increasing Access to Care
Priya Marathe
Memorial Sloan Kettering Cancer Center
$60,000
2025

A New Comprehensive Approach to Predict Long-Term Prognosis in Erdheim-Chester Disease: From Cluster Analysis to Patient-Reported Outcomes
Francesco Peyronel
Meyer Children's University Hospital-IRCCS
$50,000
2024

Inferring the origin of Erdheim-Chester Disease from phylogenetic mapping
Matthew Collin
Newcastle University
$200,000
2023

Survivorship and Symptom Burden in ECD
Gaurav Goyal
University of Alabama at Birmingham
$200,000
2023

Prognostic and Therapeutic Significance of Chromosome Region Maintenance 1 (CRM1) Protein in Erdheim Chester Disease
Jithma Abeykoon
Mayo Clinic
$20,000
2022

Spatial understanding of Erdheim-Chester Disease origin and lesional microenvironment
Egle Kvedaraite
Karolinska Institutet
$50,000
2022

Histiocytic Disorders Survivor Study (HDSS)
Gaurav Goyal
University of Alabama at Birmingham
$20,000
2021

Exploring the genetic landscape of Erdheim-Chester disease by integrating GWAS and -omic data
Francesco Pegoraro
Meyer Children's University Hospital
$50,000
2021

Pathophysiology of Neurodegenerative Erdheim-Chester Disease and Langerhans Cell Histiocytosis
Nicole Coufal
University of California
$50,000
2019

Defining the Cell-of-Origin of Erdheim-Chester Disease
Benjamin H. Durham
Memorial Sloan Kettering Cancer Center
$50,000
2017

A Clinical, Structural, and Functional Neuroimaging Study of Cognition in Erdheim-Chester Disease
Eli Diamond and Vaios Hatzoglou
Memorial Sloan Kettering Cancer Center
$43,000
2015

Understanding and targeting novel molecular alterations in Erdheim-Chester Disease without the BRAFV600E mutation
Monte Rosa Therapeutics and Memorial Sloan Kettering Cancer Center
Filip Janku and Omar Abdel-Wahab
$50,000
2015

Tailoring Treatment for Erdheim-Chester Disease
Marina Ferrarini and Lorenzo Dagna
San Raffaele Scientific Institute
$50,000
2015

Design and Creation of a Global Registry Database for Erdheim-Chester Disease
Matthew Collin and Eli Diamond
Newcastle University and Memorial Sloan Kettering Cancer Center
$316,000
2014

Somatic Genetic Alterations in the Pathogenesis and Therapy of Histiocytic Disorders
Omar Abedel-Wahab
Memorial Sloan Kettering Cancer Center
$50,000
2013

Understanding dendritic cell lineages in Erdheim-Chester disease: towards a non-invasive diagnosis
Julien Haroche and Laurent Arnaud
Hopital Pitie-Salpetriere
$47,000
2012

Hypoxia and inflammation in Erdheim-Chester disease microenvironment: insights on the pathogenesis and implications for therapy proposal
Lorenzo Dagna
IRCCS San Raffaele Scientific Institute
$49,745
2011

